Despite the substantial improvements in body weight and glucose control elicited by GLP-1R agonists, patient uptake and compliance are challenged by frequent gastrointestinal adverse events (GI AEs), including nausea and vomiting, that necessitate careful dose titration regimens to achieve efficacious exposure (14)
Oral and injectable GLP-1 therapies can both provide meaningful clinical benefits, but their performance may differ depending on the product, patient population, and treatment goals
Recalls & Warnings March 21, 2017 Plant-Based Protein Powders Recalled On March 18, 2017 Nutiva issued a recall of three plant-based protein powder shakes after determining these products may contain peanuts
McLaughlin, P
While we need more data, it's clear something significant is happening beyond just appetite suppression." Dr Sophie Dix, Head of Medical Product and Content at Levity "In clinical settings, we've observed that some patients describe feeling more emotionally balanced and less prone to acting on impulse after starting GLP-1s
